Kyverna Therapeutics Aims for First CAR T Approval in Stiff Person Syndrome
Event summary
- Kyverna anticipates submitting its first Biologics License Application (BLA) for miv-cel in stiff person syndrome (SPS) in the first half of 2026.
- The company reported $279.3 million in cash and cash equivalents as of December 31, 2025, providing a runway into 2028.
- Positive interim data from the Phase 2 portion of its KYSA-6 clinical trial for generalized myasthenia gravis (gMG) demonstrated durable, drug-free, disease-free remission.
- Kyverna raised $147.5 million through a combination of financing activities, including a $150 million milestone-based loan facility with Oxford Finance.
The big picture
Kyverna Therapeutics is positioning itself as a leader in autoimmune CAR T therapies, with a focus on addressing significant unmet needs in SPS and gMG. The company's strategic investments in clinical trials and commercial readiness underscore its ambition to establish a neuroimmunology franchise. With a strong cash position and a pipeline of promising data, Kyverna is poised to capitalize on the growing demand for innovative treatments in autoimmune diseases.
What we're watching
- Regulatory Timing
- Whether Kyverna can secure BLA approval for miv-cel in SPS by the end of 2026, setting the stage for commercial launch.
- Pipeline Progress
- The pace at which Kyverna advances its Phase 3 trial in gMG and reports additional data for progressive multiple sclerosis and rheumatoid arthritis.
- Financial Management
- How Kyverna allocates its $279.3 million in cash to support both its SPS launch and ongoing clinical trials.
Related topics